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Hypertrophic cardiomyopathy (HCM) is the most common inherited
form of heart disease, associated with over 1,000 mutations, many in
β-cardiac myosin (MYH7). Molecular studies of myosin with different
HCM mutations have revealed a diversity of effects on ATPase and
load-sensitive rate of detachment from actin. It has been difficult to
predict how such diverse molecular effects combine to influence
forces at the cellular level and further influence cellular phenotypes.
This study focused on the P710R mutation that dramatically decreased in vitro motility velocity and actin-activated ATPase, in contrast to other MYH7 mutations. Optical trap measurements of single
myosin molecules revealed that this mutation reduced the step size
of the myosin motor and the load sensitivity of the actin detachment
rate. Conversely, this mutation destabilized the super relaxed state in
longer, two-headed myosin constructs, freeing more heads to generate force. Micropatterned human induced pluripotent derived stem
cell (hiPSC)–cardiomyocytes CRISPR-edited with the P710R mutation
produced significantly increased force (measured by traction force
microscopy) compared with isogenic control cells. The P710R mutation also caused cardiomyocyte hypertrophy and cytoskeletal remodeling as measured by immunostaining and electron microscopy.
Cellular hypertrophy was prevented in the P710R cells by inhibition
of ERK or Akt. Finally, we used a computational model that integrated the measured molecular changes to predict the measured
traction forces. These results confirm a key role for regulation of
the super relaxed state in driving hypercontractility in HCM with the
P710R mutation and demonstrate the value of a multiscale approach
in revealing key mechanisms of disease.
hypertrophic cardiomyopathy
CMs super relaxed state

|

Significance
Heart disease is the leading cause of death worldwide, and hypertrophic cardiomyopathy (HCM) is the most common inherited
form of heart disease, affecting over 1 in 200 people. Mutations
in myosin, the motor protein responsible for contraction of the
heart, are a common cause of HCM but have diverse effects on
the biomechanics of the myosin protein. We demonstrate that
complex biomechanical effects of mutations associated with
heart disease can be effectively studied and understood using a
multiscale experimental and computational modeling approach.
This work confirms an important role for disruption of the super
relaxed state for one particular HCM mutation and provides an
approach that can be extended to aid in the understanding of
disease mechanisms for different mutations.

| β-cardiac myosin | optical trapping | hiPSC-
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remodeling in some patients with HCM mutations in β-cardiac
myosin (9).
Because hypercontractility is often observed in HCM patients
with mutations in β-cardiac myosin, HCM mutations were hypothesized to increase the activity of myosin at the protein level,
resulting in increased force production at the sarcomere and cellular levels that propagates to the whole-organ level (10). Myosin
protein activity is characterized by biochemical and biophysical
measurements. The activity of actively cycling myosin interacting
with actin is characterized by the rate of ATP turnover, the rate of
detachment from actin, force production, step size, and actin-sliding
velocity. Myosin that is not actively cycling resides in a super relaxed
state (SRX) (11), associated with a folded-back conformation not

ypertrophic cardiomyopathy (HCM) is one of the most
prevalent genetic diseases of the heart, affecting over 1 in
200 individuals (1, 2), and is a leading cause of sudden cardiac
death (3). HCM is characterized by cardiomyocyte hypertrophy,
myofibril disarray, hypercontractility, and diastolic dysfunction,
although there are substantial heterogeneity and complexity in
the presentation of HCM in patients (4, 5). Tissue remodeling,
including interstitial fibrosis, can eventually progress to heart
failure and death (5–7). Over 1,000 causative mutations have
been identified, with the majority in genes encoding sarcomeric
proteins responsible for generating and regulating contraction.
Roughly a third of mutations are located in β-cardiac myosin, the
primary ventricular motor protein in humans (8). Increased ejection fraction has been observed in patients with pathogenic mutations in β-cardiac myosin without left ventricular (LV) hypertrophy,
which suggests that hypercontractility may precede hypertrophic
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available for actin interaction. Biochemical and biophysical assessments of HCM mutations in purified human β-cardiac myosin
have revealed various changes in both actively cycling myosin
(12–16) and SRX proportions (17–20).
Myosin is a mechanoenzyme that harnesses the chemical energy from ATP hydrolysis to perform a force-producing power
stroke. Its converter domain plays a critical role in facilitating
this power stroke by coupling conformational changes originating from its nucleotide pocket to the rotation of its lever arm.
This domain is a hot spot for pathogenic mutations (21–24). The
P710 residue is located at the proximal edge of the converter domain, and at least three HCM mutations have been identified at
this site, including P710R (25–27). The P710R mutation was
identified in a cohort of patients with pediatric onset HCM (defined based on LV hypertrophy in patients 13 or younger), and
echocardiograms of this cohort found significantly reduced LV end
systolic dimension and increased fraction shortening suggesting
hypercontractility (27). According to a recent meta-analysis, the
average age of disease onset for HCM in patients without a known
mutation is 44 y, and the average age of onset with mutations in
β-cardiac myosin is 35 y (28). A previous report characterizing both
early-onset and late-onset HCM mutations found that actively cycling heads with the P710R mutation have lower ATP turnover
activity and duty ratio compared with both wild-type (WT) myosin
and other HCM mutations (29). The discrepancy between this
reduced function in actively cycling myosin and a potentially
hypercontractile, early-onset clinical phenotype invites a comprehensive, multiscale assessment of the effects of the P710R mutation on myosin activity and SRX proportions.
In the past, it has been difficult to determine early mechanisms of
HCM disease triggered by mutations in β-MHC because of the
inability to culture human cardiomyocytes. Samples from hearts
obtained at the time of transplant or myectomy reflect a combination of primary and secondary pathologies. Rodents fail to recapitulate many human heart diseases, and their adult ventricles
predominantly express the α-MHC isoform, which has different
kinetics from β-MHC (30–32). However, the expansion of CRISPR/
Cas-9 protocols for human induced pluripotent derived stem cell
(hiPSC) gene editing coupled with efficient differentiation into
cardiomyocytes (hiPSC-CMs) provides a valuable model system for
studying early mechanisms of disease, especially mechanisms related to contractile alterations, in a controlled context (31). In the
past, hiPSC-CM models have been limited by the relative immaturity of the cardiomyocytes and high population heterogeneity (33).
In traditional two-dimensional culture, these cells have disorganized
myofibrils, impaired calcium handling, and immature cell signaling
(34, 35). However, recent advances in microengineered environments can provide external environmental cues that better recapitulate in vivo conditions to promote myofibril alignment and
accelerate maturation of both contractile machinery and cell signaling (35, 36). While these engineering solutions can improve the
functional maturity of hiPSC-CMs, they are still immature relative
to adult cardiomyocytes in the heart (33). We have previously developed a hydrogel platform with rectangles of extracellular matrix
(ECM) at a 7:1 aspect ratio (similar to that of cardiomyocytes in the
left ventricle) that, combined with traction force microscopy (TFM),
allows for single-cell assessment of both cellular organization and
biomechanics (35–37). When combined with measurements of
myosin function at the molecular level, these cellular measurements
can provide validation of the molecular basis of force generation
and resultant disease mechanisms of HCM.
Finally, computational models can provide key insights into the
interactions between related dynamic parameters and the resultant implications for the total production of force. Computational
models incorporating different degrees of detail and different
components of sarcomere structure have been used for decades to
answer questions relating to fundamental muscle mechanics
(38–47) and alterations to thin filament regulation in the context
2 of 12 | PNAS
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of cardiac disease and HCM (48, 49). A new model of myosin
activity that incorporates an OFF state representative of the SRX
state has recently been validated against experimental measurements of cardiac muscle (50). This study concluded that forcesensitive regulation of the OFF state significantly improves the
fit to experimental data, but this model has not previously been
used in the context of MHY7 mutations nor hiPSC-CMs (50).
In this work, we used multiscale experimental techniques to
assess the biomechanical effects of the HCM mutation P710R,
which demonstrates decreased activity at the level of the motor
domain yet increased force generation at the cell level. We furthermore used a computational model to integrate the molecular
findings and found that altered regulation of the SRX state is an
essential driver of hypercontractility for this mutation. Our multiscale experimental findings combined with computational modeling enabled us to assess the relative contributions of individual
molecular parameters to cellular contraction.
Results
The P710R Mutation Reduced Load Sensitivity and Step Size of Single
Myosin Molecules. We first focused on the motor domain of my-

osin by using the recombinant human β-cardiac myosin sS1 domain (catalytic domain plus the essential light chain binding
portion of the lever arm). The properties of individual myosin
heads interacting with actin were assessed by optical trapping
using harmonic force spectroscopy (HFS). In this technique, the
durations of binding events between a single myosin and an actin
filament under different load forces are measured in physiological (2 mM) ATP conditions. The sample stage oscillates sinusoidally so that by the randomness of where myosin initially
attaches to actin, a range of mean forces are automatically applied
over the course of many binding events (51). This technique has
been used to quantify changes in the load-dependent detachment
rate of β-cardiac myosin due to mutations and myosin inhibitor
and activators (14).
The detachment rate is an exponential function of the mean
load force (F):
ΔFδ k−FδT
kdet ( F, ΔF ) = k0 I0 (
)e B ,
kB T

[1]

where k0 is the rate at zero load, δ is the distance to the transition
state of the rate-limiting step in the bound state (a measure of
force sensitivity), kB is the Boltzmann constant, T is temperature,
and I0 is the zeroth-order modified Bessel function of the first
kind (to correct for the harmonic force with amplitude ΔF). The
release of ADP is the rate-limiting step for detachment from actin
at high (2 mM) ATP concentrations, and this step is sensitive to
load force. Thus, the detachment rate k0 and its load sensitivity δ
determined by HFS correspond to the rate of ADP release and its
load sensitivity, respectively. WT β-cardiac myosin had detachment rate at zero load k0 = 104 ± 10 s−1 and force sensitivity
δ = 1.39 ± 0.06 nm (results from 8 molecules), consistent with
previous results (14, 51–53). The unloaded detachment rate of
P710R was not significantly changed (87 ± 5 s−1, P = 0.12), while
δ was dramatically reduced (0.31 ± 0.03 nm, P < 0.0001) (results
from 13 molecules) (Table 1 and Fig. 1 A and B). Consistent with
our single-molecule finding of an unchanged unloaded detachment
rate, previous ensemble stopped-flow measurements had found that
P710R did not alter the rate of ADP release, the rate-limiting step
for detachment from actin (29). Our single-molecule trap experiments reveal that this rate of ADP release is rendered much less
sensitive to load forces as a result of the mutation.
Further analysis of the average trapped bead displacement
during binding events revealed that the mutation decreased myosin’s
step size by ∼60% (WT, d = 5.2 ± 0.3 nm; P710R, d = 1.9 ± 0.3 nm;
Vander Roest et al.
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Table 1. Parameters measured for β-cardiac myosin sS1
k0, s−1

δ, nm

kcat, s−1

d, nm

Kapp, μM

V, nm·s−1

pCa50

n

WT
104 ± 10 1.39 ± 0.06
5.2 ± 0.3
4.1 ± 0.4 33 ± 6 762 ± 16
6.46 ± 0.04 2.2 ± 0.2
P710R 87 ± 5 0.31 ± 0.03**** 1.9 ± 0.3**** 2.5 ± 0.1* 14 ± 1* 239 ± 9**** 6.48 ± 0.07 3.1 ± 0.6
The rate of detachment from actin at zero load k0, its force sensitivity δ, and myosin’s step size d were
measured from single molecules using the HFS technique (8 WT and 13 P710R molecules). kcat and Kapp were
measured using a colorimetric actin-activated ATPase assay and were previously reported (29). Unloaded motility
velocities V were measured by the motility assay with actin filaments (nine WT and eight P710R independent
experiments). Calcium sensitivity parameters pCa50 and Hill coefficient n were measured by motility assay with
regulated thin filaments (five WT and four P710R independent experiments). Data are presented as mean ± SEM.
*P < 0.05 and ****P < 0.0001 different between P710R and WT.

P < 0.0001) (results from 8 WT and 13 P710R molecules) (Table 1
and Fig. 1C and SI Appendix, Fig. S1).

where the attachment rate kattach, calculated at saturating actin
concentrations and assumed to be independent of force, is given
by the following:
kattach =

fects of the P710R mutation on properties of myosin sS1 in ensemble. It has been previously reported that myosins with the
P710R mutation had significantly reduced actin-activated ATPase
activity at saturating actin concentrations (WT, kcat = 4.1 ± 0.4 s−1;
P710R, kcat = 2.5 ± 0.1 s−1) but higher apparent actin affinity (WT,
Kapp = 33 ± 6 μM; P710R, Kapp = 14 ± 1 μM) (29) (Table 1). Given
the single-molecule and ensemble ATPase measurements, the duty
ratio can be estimated as a function of load force (F) (14):
dr ( F ) =

kattach
,
kattach + kdet ( F )

[3]

Our calculations suggest that P710R has a much lower duty ratio
than WT myosin at low or resistive (positive) loads (Fig. 2A),
consistent with a previously reported prediction (29). Since duty
ratio is the fraction of total cycle time that a myosin head spends in
the bound force-producing state, P710R is predicted to have a
lower time-averaged force per head than WT at those loads.
Our calculations predict that P710R has a slightly higher duty ratio
than WT under high assistive (negative) loads, suggesting that
P710R heads may not release actin as efficiently in an actively
shortening sarcomere.

[2]

Load-sensitive detachment rate
B

A

WT
P710R

****

P710R

2 nm

WT

0

0

0.05

50 ms

Step size (nm)

Step size

C
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P710R

Fig. 1. Single molecules of β-cardiac myosin sS1 with
P710R mutation had reduced load sensitivity and
step size. (A) Measurements of myosin’s loadsensitive rate of detachment from actin kdet(F) using the HFS technique in a dual-beam optical trap.
Positive forces represent load in the opposite direction of the power stroke (resistive), and negative
forces represent load in the same direction of the
power stroke (assistive). Each light line is a fit of Eq. 1
to data from one molecule, each with a few hundred
binding events. (B) The fitted parameters k0 (rate at
zero load) and δ (load sensitivity) of each molecule
corresponding to light lines in A. Error bars represent
the error in the parameter fit for each molecule.
Horizontal lines represent weighted means across all
molecules, and shaded rectangles represent SEM. (C)
Averaged start-aligned position traces of binding
events from two example molecules revealing the
power stroke of myosin, which occur within milliseconds of actin binding. Step size values of multiple
molecules are shown on the Right. Error bars represent SEM. Single-molecule data are from 8 WT molecules and 13 P710R molecules as shown. Values are
given in Table 1. See also Materials and Methods and
SI Appendix, Fig. S1. ****P < 0.0001.
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The P710R Mutation Reduced kcat, Duty Ratio, and Velocity but Not
Calcium Sensitivity of Myosin in Ensemble. We next assessed the ef-
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Taken together, the above measurements of the myosin motor
domain at the single-molecule and ensemble levels do not suggest a
clear mechanism of hypercontractility by the HCM mutation
P710R; in contrast, they would appear to suggest hypocontractility.
The P710R Mutation Disrupted the SRX State of Myosin In Vitro. We
and others have previously shown that the ability of myosin to form
the folded-back interacting-heads motif structure is critical for
regulating myosin activity, and many HCM-causing mutations appear to disrupt the ability of myosin to enter this state (17–20, 58).
To assess the ability of myosin to form this folded-back “off” state
in vitro, we used two-headed myosin constructs as previously described (20). We measured a significant 37% reduction in the actinactivated ATPase rate (kcat) of a long-tailed (25-hep) WT myosin
construct compared with a short-tailed (2-hep) WT construct (2hep, kcat = 5.6 ± 0.3 s−1·head−1; 25-hep, kcat = 3.5 ± 0.2 s−1·head−1;
P < 0.001) (results fit to data from four and two separate experiments, respectively, with three replicates per experiment) (Fig. 3 A
and B), consistent with our previous observations (17, 19, 20). This
difference can be attributed to the sequestration of a large fraction
of the myosin in the folded-back state in the long-tailed population,
thus preventing the heads from binding to actin and entering the
ATPase cycle. In contrast, we found no significant difference between the ATPase rate of the P710R short- and long-tailed myosins (P710R 2 hep, kcat = 3.7 ± 0.3 s−1·head−1; P710R 25 hep, kcat =
3.6 ± 0.3 s−1·head−1; P = 0.76) (results fit to data from two experiments with three replicates each) (Fig. 3C). This suggests that
P710R has a greatly reduced ability to access the sequestered
folded-back state.
We have previously correlated the folded-back structural state
with the proportion of basal ATP turnover at the SRX rate
(∼0.003 s−1), as opposed to the disordered relaxed state (DRX)
rate (∼0.01–0.03 s−1) (18, 58). These rates are measured using a
single mant-ATP turnover assay in the absence of actin, in which
the release of fluorescent mant-ADP from myosin is measured
over time. The signal shows a biexponential decay characterized by
two rates: The faster rate corresponds to the DRX rate, and the
slower rate corresponds to the SRX rate (Fig. 3D). Lower fractions of SRX correlate with a reduced ability to form the foldedback state [via EM imaging and ATPase (18)]. We have previously
shown that the percentage of WT 25-hep myosin hydrolyzing ATP
at the slower SRX rate was 55–65% (at a salt concentration of
5 mM KOAc), in contrast to WT 2-hep myosin, which shows
15–25% SRX (regardless of salt concentration) due to its inability
to form the folded-back state (results from three experiments)
(Fig. 3F) (17). Here, we found no significant difference in the
percentage of molecules in the SRX state between WT and P710R

C

****

Velocity (nm s-1)

Actin sliding velocity in an unloaded motility assay was reduced by ∼60% for P710R compared with WT (WT, V = 762 ±
16 nm/s from 9 experiments; P710R, V = 239 ± 9 nm/s from 8
experiments; P < 0.0001) (Table 1 and Fig. 2B and SI Appendix,
Fig. S2 and Movies S1 and S2). The conditions of our motility
experiments ensured that myosin heads were present in sufficient
numbers on the surface and had short enough tethers such that
sliding velocities were limited by filaments’ detachment from
myosin rather than by attachment (54, 55) (Materials and Methods). Under these detachment-limiting conditions, velocity can be
approximated as the step size divided by the actin-bound time,
which is inversely proportional to the actin detachment rate: v = d/
tbound = d*kdet. Thus, the 60% reduction in unloaded motility
velocity can be explained by the 60% reduction in P710R’s step
size and an unchanged unloaded detachment rate k0. A previous
study of this mutation failed to predict the measured decrease in
velocity likely because the authors did not account for a major
reduction in step size (29). We further observed that 5–15% of
actin filaments were immobile for P710R compared with 0–5% for
WT (SI Appendix, Fig. S2). This suggests that the mutation may
induce a less proper or stable protein fold in a small percentage of
myosin molecules, which, as a result, have reduced function in
moving actin (Materials and Methods and Discussion).
In addition to determining motility velocity, myosin’s actindetachment kinetics may affect the calcium sensitivity of sarcomeres through the activation of the thin filament by bound myosin
heads (47). In the thin filament, binding sites on actin are blocked
by the regulatory proteins troponin and tropomyosin when calcium levels are low (in diastole) and are activated and accessible to
myosin heads when calcium levels rise (in systole). However,
heads that stay bound to actin longer may cooperatively activate
the thin filament at lower calcium concentrations (56, 57), thereby
altering the calcium sensitivity. While P710R had an unchanged
unloaded actin-detachment rate k0, the effect of its reduced force
sensitivity δ on this mechanism of calcium sensitivity is unclear. To
this end, we measured the sliding velocities of regulated thin filaments (RTFs) (actin decorated with troponin and tropomyosin)
at various calcium concentrations in the motility assay. RTF velocities increased as calcium concentration increased through the
physiological range (pCa7-6, or 100 nM to 1 μM), and velocities
saturated at high calcium levels (pCa4) (Fig. 2C). We found that
the P710R mutation did not significantly affect the calcium sensitivity; neither the calcium concentration for half-maximum velocity
(P710R, pCa50 = 6.48 ± 0.07; WT, pCa50 = 6.46 ± 0.04; P = 0.78)
nor the Hill coefficient (P710R, n = 3.1 ± 0.6; WT, n = 2.2 ± 0.2;
P = 0.23) were significantly different from WT (results from five
WT and four P710R experiments) (Table 1 and Fig. 2C).

600
400
200
0

WT

P710R

1000
800
600
400
200
0

8

6

4

pCa

Fig. 2. β-Cardiac myosin sS1 ensembles with P710R mutation had altered duty ratio, reduced actin sliding velocity, and unchanged calcium sensitivity. (A)
Calculated duty ratio across load forces based on ATPase and actin detachment rate measurements. (B) Actin sliding velocity (mean velocity including stuck
filaments [MVIS]; Materials and Methods) in the unloaded motility assay. Each data point represents one independent experiment (n = 9 for WT, n = 8 for
P710R). (C) Velocities (MVIS) of regulated thin filaments at various calcium concentrations measured by the motility assay. pCa = −log10[Ca]. The curves are fits
to the Hill equation of averaged data from multiple independent experiments (n = 5 for WT, n = 4 for P710R), and the vertical dashed lines represent the
fitted pCa50 values. Error bars represent SEM. Values are given in Table 1. See also SI Appendix, Fig. S2. ****P < 0.0001.

4 of 12 | PNAS
https://doi.org/10.1073/pnas.2025030118

Vander Roest et al.
Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to
hypercontractility by disrupting super relaxed state

B

C

D

E

F

2-hep myosins (P = 0.12; Fig. 3F). In contrast to WT 25-hep, only
27 ± 6% of the P710R 25-hep myosin hydrolyzed ATP at the slow
rate (results from seven experiments) (P = 0.0001 vs. WT 25-hep;
Fig. 3F). The fast rate of P710R 2-hep myosin was higher than that
of WT 2-hep myosin (P = 0.004; SI Appendix, Table S1), while the
fast rate of P710R 25-hep myosin was not significantly different
from that of WT 25-hep myosin. Consistent with our 25-hep
ATPase findings, these single-turnover results confirm that the
P710R mutation reduced myosin’s ability to form the folded-back
SRX state.
To summarize our molecular studies, the P710R mutation significantly reduced the load sensitivity of the detachment rate from
actin, step size, and unloaded motility, suggesting hypocontractility.
However, the mutation also reduced the ability of myosin to form
the SRX state, suggesting hypercontractility. Thus, to understand
these competing effects, we next investigated the effects of this
mutation in human cardiomyocytes.
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The P710R Mutation Increased Traction Force Generation and Cell Size
in Micropatterned hiPSC-CMs. We used CRISPR/Cas9 gene editing

to insert a point mutation of proline to arginine in one allele of
the MYH7 gene (SI Appendix, Fig. S4). We first measured the
effects of the P710R mutation on cellular force generation using
TFM. Isolated hiPSC-CMs at 35–40 d after cardiac differentiation were cultured for 4–5 d on hydrogels of physiologic stiffness
(10 kPa) with matrigel bioprinted in a mature cardiomyocyte
aspect ratio of 7:1 (35, 37). We have previously shown that this
platform optimizes force generation and dramatically enhances
Vander Roest et al.
Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to
hypercontractility by disrupting super relaxed state

Fig. 3. β-Cardiac myosin ensembles with P710R
mutation had reduced SRX state. (A) Schematic of
protein constructs show 2 head (S1) domains (with
light chains) and a 2- or 25-heptad tail domain. (B
and C) Ensemble measurement of actin-activated
ATPase rate normalized to the kcat for WT 2-hep
from preparations performed on the same day. Each
plot shows summary data from two independent
experiments with triplicate measurements, for a total of n = 6. See also Materials and Methods and SI
Appendix, Fig. S3. Error bars represent SEM of measurements, and shading represents error of the fit. (D
and E) Representative traces of mant-ATP single
turnover in the short (2-hep)- and long (25-hep)tailed protein constructs. (F) Quantification of the %
SRX in WT and P710R myosins (n = 3 for WT, n = 7 for
P710R 2-hep, and n = 6 for P710R 25-hep). Error bars
represent SEM. WT data (D and F) was previously
reported (17). ***P < 0.001. A, D–E: Adapted from
ref. 17, which is licensed under CC BY 4.0.

hiPSC-CM maturation (35). Patterned hiPSC-CMs with the
P710R mutation produced significantly higher total peak force
than WT controls (Fig. 4 A–C). Our single-cell platform allowed
assessment of 29 WT and 30 P710R cells from three differentiation batches (Fig. 4 C–F) and provides spatially and temporally
resolved measurements of traction force for each cell. Contraction duration—measured as the time between peak velocity of
contraction and peak velocity of relaxation as previously described
(37)—was significantly lengthened in the P710R cells (Fig. 4D).
P710R cells were significantly larger than the WT (Fig. 4E), and
the significant increase in force persisted after normalizing peak
force to cell spread area (Fig. 4F).
The P710R Mutation Caused Myofibril Disruption and z-Disk Thickening
in Patterned hiPSC-CMs. The ability of myosin to generate contractile

forces in vivo depends on its incorporation into sarcomeres and
myofibrils. Staining for β-MHC revealed organization into sarcomeres in cells grown on patterned hydrogels (Fig. 5A). Sarcomere
lengths were not significantly different between control and mutant
cells when quantified from immunostained cells (n = 11 control
and n = 15 P710R) (Fig. 5B). We confirmed this result using
transmission electron microscopy (TEM) (Fig. 5 C and D). With
both imaging techniques, while the median values were not significantly different, there was a significant increase in the range and
variability (determined by F test) of sarcomere lengths in P710R
cells compared with controls, consistent with our finding of myofiber disarray. TEM of patterned cells showed aligned myofibrils in
the WT controls and varying degrees of myofibril and sarcomeric
PNAS | 5 of 12
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disruption in many P710R cells. The degree of myofiber disarray
was quantified using the directionality tool in ImageJ, and the
degree of dispersion of directionality across the image was significantly increased in P710R cells (n = 12 control and n = 13 P710R
regions of interest) (Fig. 5E). We also observed significant thickening (measured along fiber direction) of the z disks in P710R cells
(Fig. 5F). This cytoskeletal disruption may be an indication of
cellular remodeling that ultimately leads to hypertrophy.
The P710R Mutation Caused Hypertrophic Growth of hiPSC-CMs via
Akt and ERK. We next tested whether the P710R mutation in-

creases cell size across the broader population of cells (and not
only in paceable, patterned cells). After 45 d of culture in confluent monolayers, hiPSC-CMs were replated sparsely onto
Matrigel-coated tissue culture plastic, allowed to attach and
spread for 2 d, and then fixed and stained to quantify their
spread area (n = 474 control cells and n = 151 P710R cells).
P710R cells were significantly larger than control cells (Fig. 6A).
Western blot analysis of two known hypertrophic growth signaling pathways showed increased ERK and Akt basal activation
(Fig. 6 B and C) in P710R cells (n = 6 differentiation batches).
Inhibition of these signaling proteins with previously characterized specific inhibitors (SCH772984 and Akti 1/2) (59, 60)
between days 26 and 46 resulted in significantly reduced cell area
in P710R cells relative to untreated P710R cells (n = 538, 294,

and 370 P710R cells, no treatment, ERK inhibitor, and Akt inhibitor, respectively) (Fig. 6D). However, treatment of P710R
cells with either inhibitor did not fully reduce their area to the
size of the corresponding inhibitor-treated unedited control cells
(SI Appendix, Fig. S5).
We also quantified the relative expression of β-MHC and
α-MHC in P710R cells compared with isogenic control cells with
both Western blot and qPCR (SI Appendix, Fig. S6 B–D). We
found no significant difference in β-MHC protein or transcript
levels between P710R and control cells, while α-MHC protein and
transcript levels were significantly reduced in P710R cells compared with control. However, the relative transcript levels of
α-MHC to β-MHC was less than 0.1, suggesting that the majority
of myosin heavy chain in both isogenic control and P710R cells
was β-MHC.
Computational Modeling of P710R Myosin Compared with WT Predicted
an Increase in Force When SRX Disruption Was Included. To determine

the predicted effects of individual and combined changes in myosin
kinetics on total force production, we used a previously validated
computational model of cardiac muscle contraction (50), modified
to contain an exponential load-dependent detachment rate (Fig. 7A
and SI Appendix, Fig. S7). This model includes an OFF state to
represent the SRX state of myosin, an ON state of unbound,
available myosin, and a single bound, force generating state. Actin
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Fig. 4. P710R mutation in micropatterned single hiPSC-cardiomyocytes significantly increased contractile function. (A) Representative single cells shown in
bright field and as peak traction force plots. (B) Multiple (two to four) beats were captured per cell and the averaged traces for representative cells are shown,
with shading representing the SD of force between beats. (C) Peak total force and (D) contraction time of single control (n = 29) and P710R (n = 30) cells
collected from three differentiation batches. (E) Cell spread areas were measured and used to calculate (F) cell force normalized to cell area. Representative
cells are identified with orange markers in plots of population. Data are presented as median ± 95% confidence interval. *P < 0.05, **P < 0.01, and
***P < 0.001.
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Fig. 5. P710R mutation in micropatterned hiPSC-cardiomyocytes significantly disrupted myofibril organization. (A) Immunostaining of β-cardiac myosin in
micropatterned cells (sarcomere disruption is marked with arrows) enabled (B) quantification of sarcomere length in micropatterned cells (n = 11 control and
n = 15 P710R cells). (C) Representative TEM images of patterned cells (n = 12 control and n = 13 P710R images) enabled (D) quantification of sarcomere
length, (E) dispersion degree, a measure of myofibril alignment, and (F) z-disk thickness from TEM images (57 control and 46 P710R z disks). Data are
presented as median ± 95% confidence interval. *P < 0.05.

availability is regulated by calcium availability and the fraction
bound to myosin and does not include specific states for blocked
and free binding sites. This kinetic scheme was chosen for the sake
of model parsimony and correspondence with both previously
published work and our experimental measurements, but it limits
the insights this analysis can provide into details of bound myosin
transitions and thin filament regulation. We are also assuming a
pure population of either WT or P710R myosin, whereas the genotype of our P710R cells is heterozygous, and the cells likely express a mixture of WT and P710R myosin, limiting the assessment
of cooperative effects of heterozygous myosins. We measured calcium transients in monolayers of isogenic control and P710R cells
when paced at 1 Hz (SI Appendix, Fig. S8), scaled the transients to
the range of calcium concentration previously published for this
model, and used the scaled transients as inputs for the calculations
(61) (SI Appendix, Fig. S9A). We incorporated in this model the
measured unloaded detachment rate (k0), its load sensitivity (δ),
and step size (xcb). We defined the rate of myosin attachment (kA)
from the previous modeling analysis that used our steady-state
actin-activated ATPase measurements for sS1 (29) (see Materials
and Methods for more details). We assumed that all other parameters would be unchanged between WT and P710R cells.
We did not directly measure the rates of transitioning into and
out of the SRX state, but we did measure significant differences
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in the percentage of myosins in the SRX state between WT and
P710R in the presence or absence of actin (Fig. 3). We assumed
that the % SRX of the control cells at baseline would be no more
than 90% based on some experimental measurements of SRX
regulation in cells and filaments (18, 62, 63), and we defined the
rate of opening from the OFF state (k−SRX) for control cells to
be 20 s−1. After identifying a set of parameters that successfully
predicted the measured force output of a representative control
cell (normalized to cross-sectional area), we found a best fit for
the relative increase in k−SRX to fit the force output of a representative P710R cell (Materials and Methods and SI Appendix,
Fig. S9B). This process determined that a 12.9-fold (confidence
limits 10.8- to 14.6-fold) increase in k−SRX provided the optimal
fit to the representative data. An increase in k−SRX is consistent
with the decrease in functional SRX state we measured experimentally, and the model predicted SRX% to be lower for the
P710R cell at both contracted and relaxed periods of the cardiac
cycle (SI Appendix, Fig. S9F). The rate of entering the SRX state
(k+SRX) was set to 200 s−1 for both groups based on published
data and previous modeling (50, 64). All other parameters were
held constant between control and P710R, including the rates of
thin filament activation (kon), inactivation (koff), and the cooperativity coefficient (kcoop). The changes to myosin kinetics (k−SRX,
k0, δ, and step size) were sufficient to increase the percentage of
PNAS | 7 of 12
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Fig. 6. P710R mutation in hiPSC-cardiomyocytes significantly increases cell size and activation of proteins involved in hypertrophic signaling. (A) Size of
unpatterned cells was quantified from immunostaining for cardiac troponin T (cTnT) (n = 474 control cells and n = 151 P710R cells). (B and C) Western blots
and densitometry analysis of phosphorylation of the hypertrophic signaling pathway proteins ERK (B) and Akt (C) in unpatterned cells with each P710R
sample normalized to matched isogenic control. Data are presented as mean ± SD (n = 6 differentiation batches). (D) Quantification of cell size after
treatment of P710R cells with specific inhibitors of ERK and Akt (n = 538, 294, and 370 P710R cells). (Scale bar: 50 μm.) Graphs of cell area are presented as
median ± 95% confidence interval. *P < 0.05, and ***P < 0.001.

thin filament activation and binding over the time course of contraction (SI Appendix, Fig. S9C).
The force predicted by the model after fitting parameters (SI
Appendix, Table S2) agreed well with the representative force
traces (Fig. 7B) and with the median force normalized to crosssectional area of the population of cells (Fig. 7C). Sensitivity
analysis (SI Appendix, Fig. S10) suggested that fourfold changes
in cross-bridge density up and down spans the range of 90% of
the cell forces we measured and matches the distribution of cell
data. This parameter incorporates both the number of myosin
heads per myofibril (which may vary with cell maturity and
myofibril disruption) and the density of myofibrils in a cell
(which we observed to be variable in these cells; SI Appendix, Fig.
S11). Further simulations using the best fit parameter set and
independently adding or removing each of the four measured
parameters revealed that modulation of the rate of exiting the
SRX state accounts for the majority of the measured increase in
force (Fig. 7D). An important limitation of this analysis is that it
does not distinguish between the possibility that the basal rate of
opening from the SRX state is increased, as opposed to an
equivalent reduction in the rate of returning to the SRX state (SI
8 of 12 | PNAS
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Appendix, Fig. S9). Both our sensitivity analysis (SI Appendix, Fig.
S10) and additional fitting suggest (SI Appendix, Fig. S9B) that the
effects of changing k−SRX and k+SRX are nearly mirrored. Our
results support the hypothesis that a change in the equilibrium
between the SRX state and actively cycling states is essential for
the P710R mutation to produce significant hypercontractility.
In summary, our cellular experiments confirm a hypercontractile and hypertrophic phenotype in hiPSC-CMs harboring
the P710R mutation. Furthermore, our modeling results suggest
that the measured molecular effects of P710R are consistent with
hypercontractility if and only if SRX regulation is included.
Discussion
The diversity of molecular alterations associated with HCM have
made predictions of disease penetrance, severity, and response to
therapeutics challenging. Our study demonstrates the power of an
integrated, multiscale approach to study the biomechanical effects
of mutations in myosin known to cause HCM. The P710R mutation was previously reported to have reduced ATPase activity
and motility velocity (29), suggesting in isolation that it should
reduce duty ratio and cause hypocontractility at the cellular level.
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Fig. 7. Modeling predicted that P710R-induced modulation of SRX/DRX transitions is essential for hypercontractility. (A) Model schematic with adaptation of
detachment rate to incorporate an exponential dependence on load. Moff, Mon, and MFG(x) represent the different states of myosin. Non and Noff represent
available and deactivated thin filaments, respectively. Parameters estimated or fit from in vitro experiments are shown in black, while rates held constant
between groups are shown in gray. The model predicted (B) contractile force (solid line), which was fit to force traces from representative cells (dashed lines)
normalized to cell cross-sectional area. (C) The predicted peak force (teal) fell close to the median measured force in our cell population when normalized to
cross-sectional area (n = 29 WT and n = 30 P710R), and twofold to fourfold changes to cross-bridge (cb) density relatively match the measured distribution of
data. Representative cells highlighted in orange. (D) Simulations of independent effects of the four parameters (by inclusion with WT parameters and
replacing from the best-fit mutant parameters). Zoomed-in plots are included to improve visualization of low-force traces.

In the present work, integrating molecular measurements of single
molecules and ensembles of single and two-head constructs provides a more complete picture of the molecular mechanisms that
contribute to the hypercontractility observed in single hiPSC-CMs
with this mutation. By combining both a cellular model system
and computational modeling, we were able to reveal the hypercontractile effect of this mutation, demonstrate additional HCMassociated phenotypes, and provide key insights into the driving
factors by which HCM mutations can result in hypercontractility.
Single molecules of β-cardiac myosin with the P710R mutation
have reduced step size d, preserved actin detachment rate under
zero load k0, and reduced load sensitivity δ of the actin detachment rate (Fig. 1). This combination of findings suggests a possible molecular mechanism described as follows. In WT myosin,
the converter domain, where P710 resides, couples the swing and
forces at the lever arm to the conformational changes and forces
at the nucleotide pocket. Through this coupling, load on the
lever arm affects the rate of release of ADP from the pocket,
which determines the actin detachment rate kdet. In P710R myosin, the proline-to-arginine substitution may disrupt the local
structure of the converter domain, which would result in a reduction in the described coupling. Consequently, the rate of
ADP release (the actin detachment rate, kdet) would be less
dependent on load force (smaller δ) because load placed on the
lever arm would no longer be fully conveyed to the nucleotide
pocket. Similarly, the step size d would be reduced because the
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conformational change at the pocket would no longer be fully
conveyed to the lever arm. The unloaded ADP release rate
(unloaded actin detachment rate k0) would not be affected by the
mutation presumably because the local structure of the nucleotide pocket would remain intact. Due to inherent variability
among individual molecules, as evident in our single-molecule
data (Fig. 1), the extent of disruption by P710R may vary. Thus,
P710R may cause a small percentage (on the order of 1%) of
myosin molecules to be fully dysfunctional in moving actin
(“deadheads”), resulting in the observed higher numbers of immobile actin filaments in the motility assay (SI Appendix, Fig. S2;
Materials and Methods).
We have previously observed reductions in the load sensitivity
of myosin’s actin detachment rate by cardiac myosin effectors but
not by cardiomyopathy causing mutations (14). For example, the
investigational heart failure drug omecamtiv mecarbil (OM)
dramatically reduces the detachment rate, its load sensitivity
(14), and myosin’s step size (53). As the effects of OM and
P710R share some similarities, it is important to note that residue P710 is part of the OM binding pocket in the converter
domain (65). A recent preprint reported a reduction in myosin’s
step size due to a different HCM mutation in the same region
(P712L) (66). Taken together, these results emphasize the converter domain’s critical facilitation of myosin’s power stroke and
load sensitivity and reveal various consequences of perturbing
this domain.
PNAS | 9 of 12
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A major finding of this study is that the disruption of the
folded, SRX state is a critical driver of hypercontractility with the
P710R mutation. The results of the actin-activated ATPase and
single-turnover experiments using the longer tailed 25-hep construct (Fig. 3) demonstrate that a significantly larger fraction of
myosins with this mutation are in an open, more active state than
WT control. This increases the number of heads available for
binding to actin, which we hypothesized would increase force
production. We have measured similar changes in SRX across a
range of HCM-causing mutations (17, 19), and others have
confirmed these effects in cellular and animal models (18, 62),
suggesting that SRX regulation may be a major cause of
hypercontractility in HCM. This is further corroborated by the
finding that mavacamten, a small-molecule inhibitor of myosin
that is known to increase the SRX state (18), is effective in increasing exercise performance, reducing ejection fraction and
LV mass index, and reducing symptoms in adult patients with
obstructive HCM (67). Treatment with mavacamten has also
been shown to reduce sarcomere shortening percentage, prevent
cellular hypertrophy, and increase SRX% in hiPSC-CMs with
three other HCM mutations in β-myosin (62). Our computational modeling analysis also supports the importance of destabilization of the SRX for increasing net force even when
combined with a hypocontractile change like decreased step size.
Interestingly, in contrast with previous mutations implicated in
the folded SRX state, the P710R mutation is buried inside the
converter domain and is thus unlikely to be directly involved in
interactions required to form the folded state. This suggests that,
instead, it may result in allosteric changes that indirectly reduce
myosin’s ability to form the folded SRX state. While it is impossible to parse exactly how such allostery might operate
without a high-resolution structure of human cardiac myosin in
the folded SRX state, we speculate based on models (20, 68, 69)
that perhaps the converter domain requires a uniquely bent
conformation to access the folded state, particularly in the
“blocked” head, which might be precluded when the P710R
mutation is present. Alternatively, it has previously been suggested that the converter domain of the “free” head is a docking
site for the “blocked” head (16); this surface interaction could
also be disrupted allosterically by the P710R mutation in the
internal region of the converter domain. Ultimately, these highly
speculative hypotheses can only be resolved through a highresolution structure of human β-cardiac myosin in the folded
SRX state. Regardless, this finding importantly demonstrates that
even mutations distal from predicted head–tail and head–head
interaction sites in the folded state may result in reduced SRX.
We confirmed that the P710R mutation causes hypercontractility and other key features of HCM in cardiomyocytes
using a cellular experimental model in parallel with molecular level
experiments. Using a micropatterned culture system also allowed
for measurement of cellular-scale forces that are enhanced by the
alignment of myofibrils and balanced by a physiologic-range substrate stiffness (10 kPa). This system has also been used to quantify
hypercontractility in hiPSC-CMs with HCM-causing troponin
mutations (70). The force per cross-sectional area we measured in
the cells was significantly lower than what has been reported for
mature cardiac tissue, but this is a known sign of the relative immaturity of hiPSC-derived CMs (71). Changes in myofibril force
production between stem cell-derived and mature tissue has been
shown to correspond with expression of different light chain and
troponin and tropomyosin isoforms (71, 72). The presence of
α-myosin in a fraction of these cells also likely reflects relative
immaturity and contributes to the heterogeneity of force production observed in these cells. Despite this limitation, cells with the
P710R mutation produce significantly greater force even after
normalizing for the increase in cell area (Fig. 4). There was significant variability in force production within the cell populations,
which may be due in part to differences in myofibril density
10 of 12 | PNAS
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between cells, as suggested by our modeling analysis. The P710R
mutation caused significant perturbation in alignment of myofibrils in the mutant cells, a well-described phenotype in HCM (73),
as well as an increase in the thickness of the z disk (Fig. 5). Increased z-disk thickness has been described in many cardiomyopathies (74–76), which suggests that z-disk thickening is a
conserved phenotype associated with hypercontractility and hypertrophic remodeling. Finally, we observed cellular hypertrophy,
which was mediated in part by Akt and ERK. ERK activation has
been specifically linked to concentric hypertrophy in response to
an increase in force index (force production integrated over time
of contraction) (77). By comparing cellular responses with an
isogenic control, we have more confidence that the altered biomechanical consequences of the P710R mutation are driving both
hypercontractility and additional cellular dysfunction.
The P710R mutation induces a number of profound changes
to myosin activity whose effects become easier to interpret when
integrated into a computational model. Even with similar driving
calcium transients and identical rates of thin filament activation
by calcium, the model simulations predict an increase in thin
filament activation and a lengthening of contraction time
resulting solely from the changes in myosin kinetics (specifically
the change in regulation of SRX). In simulations where only step
size, attachment and detachment rates were changed (as is true
for the sS1 construct), there were minimal effects on actin
availability (±15% change), which matches the observed similarity in pCa50 in sS1 motility with or without the mutation.
When the disruption of SRX caused by the mutation is included,
the predicted percentage of actin kept in the active state by
myosin increases by 8- to 10-fold. This large magnitude of increase is likely due in part to the low percentage of active actin
found when fitting the control cell forces. We used a simplified
model framework with only one attached state for this initial
analysis of mechanisms of force generation, but extension of this
work could include additional myosin and thin filament states that
may more accurately capture thin filament dynamics. The model
used in this study, while by no means comprehensive, provides
valuable insights into the expected individual and combined effects
of changes to myosin kinetics and biomechanical function on force
production, actin activation, and potential sources of variability.
Several important limitations of this project should be addressed.
We measured the SRX state using shortened constructs that do not
contain the full thick filament backbone and thus likely underestimate the additional stabilization of the SRX in thick filaments
in vivo. Hypertrophy measurements and assessment of protein
activation were performed on unpatterned cells grown on tissue
culture plastic or glass because it would be difficult to quantify
phosphorylation in small populations of cells recovered from patterned gel platforms. This modeling work shows the singular effects
of a mutation, but does not fully capture potential synergistic or
emergent consequences of a mixture of control and mutant myosins acting together. Furthermore, this modeling approach assumes
that muscle force is felt uniformly throughout the muscle, while in
reality, the spatial distribution of myosins within a sarcomere can
have profound effects on the force experienced by individual myosin heads. Future modeling could incorporate spatially explicit
information that could provide even more detail on the effects of
local loads and heterotypic myosin effects.
In summary, the P710R mutation reduces several functional
parameters of the isolated myosin molecule; however, dysregulation of the SRX state appears to be the major driver of
hypercontractility. When expressed as a heterozygous mutation
in human stem cell-derived cardiomyocytes, this mutation causes
hypercontractility, myofibril disruption, and hypertrophy mediated in part through ERK and Akt. This project also demonstrates the value of computational modeling integrated with
multiscale measurements to give insights into the interactions of
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Molecular Measurements of Myosin Function in Transgenic Human Proteins
with P710R Mutation. Recombinant human β-cardiac myosin protein constructs (short subfragment 1 [sS1], short-tailed [2-hep], and long-tailed [25hep]) were expressed in C2C12 mouse myoblast cells and purified as previously described (13, 20). The load-dependent detachment rates of WT and
P710R sS1-eGFP molecules were measured in a dual-beam optical trap using
the HFS method previously described (14, 51, 78) with slight modifications.
The step sizes of myosins were determined from the same HFS data by
adapting the ensemble averaging method (79) to HFS’s oscillatory data. For
each molecule, position traces of all events were aligned at the start of
binding, extended to the length of the longest event, and averaged. Then
the oscillations were removed by subtracting a fitted sine function. The total
step size for each molecule was taken as the difference between the initial
position and the end position of the extended, averaged, sine-subtracted
traces. Motility measurements of WT and P710R sS1-AC were performed
using our previously described motility assay (32, 80) with some modifications. Motility measurements with regulated thin filaments were performed
using recombinant human troponin complex and bovine cardiac tropomyosin (81). NADH-coupled ATPases were used to compare the activity of the
2-hep and 25-hep constructs of WT and P710R β-cardiac myosin as previously
described (82). Single-turnover experiments were performed as previously
described (17, 18), using WT and mutant versions of human β-cardiac 2-hep
and 25-hep. Additional details are included in the SI Appendix.

for cardiac troponin T to measure cell area. To clarify the effect of ERK and
Akt, the cells were treated with either Akt inhibitor (Akti 1/2; Tocris; 5 μM) or
and ERK inhibitor (SCH772984; SelleckChem; 1 μM) every 3 d between day 26
and day 46 (a time frame over which hiPSC-CMs have been shown to increase in area). Additional details are included in the SI Appendix.
Implementation of Computational Model. We used a previously validated
continuum model that incorporates discretized flux equations to describe
transitions of myosin heads and thin filaments from inactive to active/bound
states and provides prediction of active and passive force (50, 85). The rate of
myosin detachment from actin was adapted to match the measured exponential load dependence, and the relative change in k-SRX was fit using experimental force measurements from representative hiPSC-CMs. Additional
details about model implementation are included in the SI Appendix.
Data Availability. All study data are included in the article and/or supporting
information. Previously published data were used for this work (17).

Measurements of Functional Consequences of P710R Mutation in Gene Edited
hiPSC-CMs. The control human iPSC line (Stanford Cardiovascular Institute
[SCVI-113]) was obtained from the Stanford CVI iPSC Biobank. The P710R
mutation was edited into these cells using a method that has been described
previously (83, 84). Cells were differentiated and their contractile function
was assessed on micropatterned hydrogels gels as previously described (35,
37). Cells on micropatterened gels were fixed and stained for β-cardiac
myosin and their sarcomere length quantifed. Cells were also plated onto
micropatterned film and imaged with TEM. Unpatterned cells were stained
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